Vaccine against meningitis B will be effective against gonorrhea


  • Gonorrhea is a sexually transmitted infection (STI) caused by the bacteria Neisseria gonorrhoeae. It is usually spread through sexual contact.
  • Most people affected by gonorrhea are between the ages of 15 and 49.

In Australia, the government has funded a meningitis B vaccination campaign, open from 1 October 2018 to children 0-3 years of age, adolescents aged 15-16 and 17-year-olds from 1 February 2019 For young adults aged 20. For this program two years after implementation, researchers from the Australian University of Adelaide and the Women’s and Children’s Health Network wanted to evaluate the effectiveness of vaccines against serogroup B meningococcal disease and gonorrhea. To do this, he conducted a study published in the journal lancet infectious disease 12 April.

To carry out their work, the scientists analyzed data on vaccination coverage through an Australian vaccination registry and information on the number of meningitis B and gonorrhea cases in the country. “Vaccine effectiveness was estimated as the reduction in the likelihood of infection using screening and case control methods. The incidence rate as a ratio obtained by comparing the number of cases each year before and after the start of the vaccination program The vaccine effect was estimated”, the authors said.

Effective at about 33%

According to the results, the incidence of serogroup B meningococcal infection was significantly reduced in infants aged 12 weeks to 11 months, but not in children aged one, two or four years. “Two doses of meningitis vaccine were 32.7% effective against gonorrhea in adolescents and young adults,” Can we read in searches.

See also  After controversy at Sci-Po Grenoble, alumni revolt and call for reform

“The unprecedented scale of Australia’s meningitis vaccination program provides valuable real-world evidence of vaccine effectiveness against meningitis in children and adolescents, and against gonorrhea in adolescents and young people. Information for establishing global meningitis vaccination programs and policy decisions.” Is necessary”, Study lead author Helen Marshall said in a statement.

You May Also Like

About the Author: Abbott Hopkins

Analyst. Amateur problem solver. Wannabe internet expert. Coffee geek. Tv guru. Award-winning communicator. Food nerd.

Leave a Reply

Your email address will not be published.